Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01234519 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
A Phase 1 study, sponsored by AEterna Zentaris.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01234519 is a Phase 1 study that was terminated before completion, run by AEterna Zentaris. The registered enrollment target is 12 participants.
The verdict
NCT01234519, a Phase 1 study, was terminated before completion, sponsored by AEterna Zentaris.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the appropriate dose of AEZS-108 to treat patients with a tumor of the urinary system.
Interventions
- DRUG AEZS-108
- DRUG AEZS-108 at MTD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-11 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01234519
The ClinicalTrials.gov registry entry for NCT01234519 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AEterna Zentaris, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AEZS-108 is the first listed.
NCT01234519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01234519 about?
NCT01234519 is a clinical study titled "A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy". The purpose of this study is to determine the appropriate dose of AEZS-108 to treat patients with a tumor of the urinary system.
What is the current status of trial NCT01234519?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2010-11. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01234519?
The interventions under investigation include: AEZS-108 (DRUG), AEZS-108 at MTD (DRUG).
Who is sponsoring clinical trial NCT01234519?
This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.